Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guérin for Bladder Cancer: A Systematic Review and Meta-Analysis.

Cancers (Basel) · 2026 · PMC13024882 · PMID 41899592

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the point estimate in the BCG-refractory subgroup suggested a trend toward a lower risk of progression with gemcitabine, the confidence interval crossed unity and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.